Meeting
2019 Gastrointestinal Cancers Symposium
The influence of renal function on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subgroup analysis of JCOG1113.
Authors
Makoto Ueno
Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Yokohama, Japan
Makoto Ueno , Chigusa Morizane , Takuji Okusaka , Gakuto Ogawa , Yuya Sato , Masafumi Ikeda , Masato Ozaka , Kazuya Sugimori , Akira Fukutomi , Hiroki Hara , Nobumasa Mizuno , Hiroaki Yanagimoto , Keiji Sano , Kazutoshi Tobimatsu , Kei Yane , Shoji Nakamori , Naohiro Sata , Tomohiro Nishina , Hiroshi Ishii , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 368)
DOI
10.1200/JCO.2019.37.4_suppl.368
Abstract #
368
Poster Bd #
K8
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
The influence of major hepatectomy on gemcitabine-based chemotherapy for advanced biliary tract cancer: An exploratory subset analysis of JCOG1113.
First Author: Tatsuya Okuno
Poster
2017 Gastrointestinal Cancers Symposium
Frequency of severe neutropenia occurring as an adverse events of gemcitabine plus cisplatin chemotherapy in patients with recurrent biliary tract cancer compared to those with unresectable biliary tract cancer.
First Author: Noriko Fujishiro
Poster
2015 ASCO Annual Meeting
Randomised phase III study of gemcitabine, cisplatin plus S-1 (GCS) compared with gemcitabine plus cisplatin (GC) for unresectable or recurrent biliary tract cancer (KHBO1401-MITSUBA).
First Author: Tatsuya Ioka
Poster
2014 ASCO Annual Meeting
Randomized phase III study of gemcitabine plus S-1 combination therapy versus gemcitabine plus cisplatin combination therapy in advanced biliary tract cancer: A Japan Clinical Oncology Group study (JCOG1113).
First Author: Chigusa Morizane